CN114206863A - 制备抗胆碱药的连续方法 - Google Patents

制备抗胆碱药的连续方法 Download PDF

Info

Publication number
CN114206863A
CN114206863A CN202080049646.2A CN202080049646A CN114206863A CN 114206863 A CN114206863 A CN 114206863A CN 202080049646 A CN202080049646 A CN 202080049646A CN 114206863 A CN114206863 A CN 114206863A
Authority
CN
China
Prior art keywords
anticholinergic
bromide
continuous flow
propanol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080049646.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡茨
N·托雷斯洛伦索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Scientia Ltd
Original Assignee
Hovione Scientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71120199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114206863(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hovione Scientia Ltd filed Critical Hovione Scientia Ltd
Publication of CN114206863A publication Critical patent/CN114206863A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080049646.2A 2019-06-17 2020-06-16 制备抗胆碱药的连续方法 Pending CN114206863A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT115583A PT115583B (pt) 2019-06-17 2019-06-17 Processo contínuo para a preparação de medicamentos anticolinérgicos
PT115583 2019-06-17
PCT/GB2020/051448 WO2020254791A1 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Publications (1)

Publication Number Publication Date
CN114206863A true CN114206863A (zh) 2022-03-18

Family

ID=71120199

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080049646.2A Pending CN114206863A (zh) 2019-06-17 2020-06-16 制备抗胆碱药的连续方法

Country Status (10)

Country Link
US (1) US20220251078A1 (https=)
EP (1) EP3982923B1 (https=)
JP (2) JP2022549545A (https=)
KR (1) KR20220024433A (https=)
CN (1) CN114206863A (https=)
AU (1) AU2020296972B2 (https=)
CA (1) CA3141271A1 (https=)
IL (1) IL288972A (https=)
PT (1) PT115583B (https=)
WO (1) WO2020254791A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203513A (zh) * 2005-05-02 2008-06-18 贝林格尔·英格海姆国际有限公司 噻托溴铵的晶型
CN103172481A (zh) * 2011-12-22 2013-06-26 百福微生物有限公司 使环叔胺类烷基化的连续方法
CN104619706A (zh) * 2012-08-15 2015-05-13 葛兰素集团有限公司 化学方法
WO2018087561A1 (en) * 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
RU2453547C2 (ru) 2005-12-19 2012-06-20 Сикор Инк. Новые формы тиотропия бромида и способы их получения
US8163913B2 (en) 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
JP5333342B2 (ja) 2009-06-29 2013-11-06 株式会社デンソー 半導体装置
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
CZ27764U1 (cs) 2014-08-22 2015-02-02 Zentiva, K.S. uMethanolový solvát umeclidinium bromidu
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203513A (zh) * 2005-05-02 2008-06-18 贝林格尔·英格海姆国际有限公司 噻托溴铵的晶型
CN103172481A (zh) * 2011-12-22 2013-06-26 百福微生物有限公司 使环叔胺类烷基化的连续方法
CN104619706A (zh) * 2012-08-15 2015-05-13 葛兰素集团有限公司 化学方法
WO2018087561A1 (en) * 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide

Also Published As

Publication number Publication date
PT115583A (pt) 2021-06-03
IL288972A (en) 2022-02-01
EP3982923B1 (en) 2024-05-15
EP3982923A1 (en) 2022-04-20
JP2025081547A (ja) 2025-05-27
WO2020254791A1 (en) 2020-12-24
CA3141271A1 (en) 2020-12-24
EP3982923C0 (en) 2024-05-15
KR20220024433A (ko) 2022-03-03
PT115583B (pt) 2022-05-02
AU2020296972A1 (en) 2022-01-20
JP2022549545A (ja) 2022-11-28
AU2020296972B2 (en) 2025-04-24
US20220251078A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US11634377B2 (en) Fenfluramine compositions and methods of preparing the same
JP2019515024A (ja) ボルチオキセチンのパモ酸塩及びその結晶形
IE59056B1 (en) 4-benzyl-1-(2h)-phthalazinone derivatives
JP2022088623A (ja) 臭化ウメクリジニウムの調製プロセス
CN103965179B (zh) 作为m3毒蕈碱性受体拮抗剂的吡咯烷鎓衍生物的多晶型物、其制备方法及药物组合物
AU2017376363A1 (en) Class of bifunctional compounds with quaternary ammonium salt structure
EP3982923B1 (en) Continuous process for the preparation of anticholinergic drugs
ES2986962T3 (es) Proceso continuo para la preparación de fármacos anticolinérgicos
JP7705351B2 (ja) ＰＬＫ４阻害剤である（１Ｒ，２Ｓ）－（Ｅ）－２－（３－（４－（（ｃｉｓ－２，６－ジメチルモルホリノ）メチル）スチリル）－１Ｈ－イミダゾール－６－イル）－５’－メトキシスピロ［シクロプロパン－１，３’－インドリン］－２’－オンフマル酸塩のＳ４結晶形
US20220402861A1 (en) A Crystalline form of (R)-terbutaline Hydrochloride
US10662152B2 (en) Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
CN111574529A (zh) 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物
US12398100B2 (en) Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JPH06510064A (ja) 置換イミダゾベンズオキサジン−１−オンの誘導体及び該誘導体の製造方法
JP2012519680A (ja) ジヒドロベンゾオキサゾール−６−イル−アセトアミド誘導体の新規結晶性水和物、非晶質体、多形体およびその調製プロセス
KR20130099132A (ko) 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
HK40107150A (en) Fenfluramine compositions and methods of preparing the same
HK1181769A (en) Process for the preparation of glycopyrronium chloride
HK1212989B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptro agonist activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination